Phio Pharmaceuticals Corp.
PHIOHealthcare|Biotechnology|US
$0.80
+0.00 (+0.16%)
DCF Value
$3.45
Tangible Book / Share
$0.74
Cash / Share
$0.91
About
Phio Pharmaceuticals Corp., a clinical stage biopharmaceutical company, engages in the development of immuno-oncology therapeutics in the United States. It develops PH-762, an INTASYL compound designed to reduce the expression of PD-1 in multi-center Phase 1b dose-escalating clinical trials; PH-894, an INTASYL compound that is designed to specifically silence BRD4, a protein that controls gene expression in both T cells and tumor cells in preclinical studies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was founded in 2003 and is based in King Of Prussia, Pennsylvania.
Stock Price
-45.9%(1Y)
1M
-17.7%
3M
-23.0%
6M
-25.1%
YTD
-23.7%
1Y
-48.3%
3Y
-92.2%
5Y
-99.6%
Pipeline Summary
2 total trials2
Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
Completed: 1Active: 1
Active Trials (1)
Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors
NCT05902520HNSCC
Phase 1Active
Enrollment: 18 participants
Key Facts
Market Cap$9.3M
Employees6 (+20% YoY)
CEORobert L. Bitterman
IPO DateMay 10, 2012
Beta0.92
52-Week Range$0.75 – $1.88
Avg Volume468,938
ExchangeNASDAQ
Websitephiopharma.com
Ownership
Float96.9%
Shares Outstanding11.6M
Recent Insider Trades
Plott Ronald ToddBUY
Sep 29, 20265,000 shares @ $1.04
Plott Ronald ToddBUY
Sep 28, 20265,000 shares @ $1.03
Carson Lisa CabottAWARD
Sep 28, 2026108,000 shares
Bitterman Robert JAWARD
Sep 28, 2026400,000 shares
Plott Ronald ToddAWARD
Sep 28, 202617,000 shares
Peers
Recent News
Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)
Nov 6, 2026 · newsfilecorp.com
Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation
Nov 5, 2026 · newsfilecorp.com
Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series
Oct 19, 2026 · newsfilecorp.com
Phio Pharmaceuticals Announces Successful Completion of First Commercial-Scale cGMP Batch of PH-762 Drug Substance
Oct 13, 2026 · feeds.newsfilecorp.com
Phio Pharmaceuticals Highlights 85% Response Rate as PH-762 Nears Phase 2b
Oct 11, 2026 · defenseworld.net
Data last updated: Nov 9, 2026, 04:28 AM